# Bortezomib and Antiviral Therapy Followed By Effusion Drainage, Bevacizumab, and Combination Chemotherapy in Treating Patients With Primary Effusion Lymphoma

> **NCT00217503** · PHASE2 · COMPLETED · sponsor: **National Cancer Institute (NCI)** · enrollment: 15 (estimated)

## Conditions studied

- Lymphoma

## Interventions

- **BIOLOGICAL:** bevacizumab
- **BIOLOGICAL:** filgrastim
- **BIOLOGICAL:** pegfilgrastim
- **DRUG:** bortezomib
- **DRUG:** cyclophosphamide
- **DRUG:** doxorubicin hydrochloride
- **DRUG:** etoposide
- **DRUG:** ganciclovir
- **DRUG:** valganciclovir
- **DRUG:** zidovudine

## Key facts

- **NCT ID:** NCT00217503
- **Lead sponsor:** National Cancer Institute (NCI)
- **Sponsor class:** NIH
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2005-07
- **Primary completion:** —
- **Final completion:** 2007-06
- **Target enrollment:** 15 (ESTIMATED)
- **Last updated:** 2013-06-20


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00217503

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00217503, "Bortezomib and Antiviral Therapy Followed By Effusion Drainage, Bevacizumab, and Combination Chemotherapy in Treating Patients With Primary Effusion Lymphoma". Retrieved via AI Analytics 2026-06-10 from https://api.ai-analytics.org/clinical/NCT00217503. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*